The Global Premier Conference for Age-related Disease Therapeutics
The race to deliver safe, effective therapies that target the biology of aging has never been more urgent, or more achievable. With a surge of biotechs now advancing into Phase 1 and 2 trials, momentum is building fast.
In 2026, the focus shifts from promise to proof, as the first wave of aging-targeted therapeutics delivers new human trial data and moves closer to regulatory validation.
Join 40+ senior executives, investors, and service providers in San Francisco to shape the future of age-related disease therapeutics. This is your chance to learn from the leader’s making history in the clinic, engage directly with C-level peers, and position yourself at the forefront of the next frontier in drug development.
A Unique Meeting
The summit is the only meeting dedicated exclusively to tackling arduous regulatory pathways, translational bottlenecks, and validating predictive biomarkers and models:
A powerhouse speaker faculty with over 50% C-suite representation, ensuring every discussion is led by the decision-makers shaping strategy and partnerships
Navigating regulatory and indication strategy, ensuring translational programs can meet FDA requirements despite aging not being a disease
New data revealed from first-in-human trials, offering delegates a front-row seat to the breakthroughs that are setting benchmarks for clinical success in this space
Exclusive investor perspectives, with leading venture funds and pharma scouts sharing how they evaluate risk, pipeline potential, and inflection points in aging therapeutics
Unmissable Event Highlights
Navigating the Regulatory Landscape
Explore the strategic and regulatory complexities of aging therapeutics in two interconnected workshops designed to accelerate clinical success. Join CEOs, regulators, founders, and investors to identify high-impact indications with measurable endpoints and early-biomarker cohorts, while avoiding broad strategies that hinder approval.
Walk away with practical frameworks to optimize trial design, accelerate regulatory pathways, and increase the likelihood of advancing your therapy into the clinic.
Hear From:
• Alexander Pickett, Managing Director, Juvenescence
• Frederick Beddingfield, Chief Executive Officer & Director, Rubedo Life Sciences
• Szilard Voros, Founder & Chief Executive Officer, Global Genomics Group, LLC
• Daniel Oliver, Chief Executive Office & Founder, Rejuvinate Bio
• Francisco Leon, Chief Executive Officer & Founder & Chairman, Tolerance Bio
• Victor Olmos, Associate, Kendal Capital Partners
Modeling in Human Aging
Discover how using complex human cellular models and bio-artificial tissues to better capture aging physiology in preclinical research. Explore how deeper understanding of mitochondrial health, cellular fate, and the hallmarks of aging can restore function and improve predictability in translation.
Walk away with a toolkit of cutting-edge approaches to improve model fidelity, reduce costly failures, and accelerate discovery into clinical relevance.
Hear From:
• Anne-Ulrike Trendelenburg, Executive Director, at Novartis
Investing in Geroscience
Gain an inside look at how leading investors are evaluating longevity-focused startups and clinical programs. Learn how to define inflection points from IND to proof-of-mechanism, build de-risking strategies with biomarkers and partnerships, and attract capital in a competitive space.
Walk away with the investor perspective you need to strengthen your fundraising strategy, validate your pipeline, and secure partnerships to fuel long-term growth.
Hear from:
• Alex Colville, General Partner at Age1
Explore the Industry-Dedicated Agenda
- 40+ industry attendees
- 20+ world class speakers
- 5+ hours of dedicated networking
- 3 content-packed days from senior-level industry experts
- 2 interactive workshops with regulatory, C-suite, and investor insights
Attending Companies Include
Explore the Agenda
Dive into interactive workshops, investor panels, and case-study–led presentations to unlock exclusive insights into age-related disease drug development.
Partner With Us
Align your brand with pioneering biopharma leaders and place your preclinical models, biomarkers, and assays at the heart of a multi-billion-dollar market.
Connect With Age-Related Experts
Join dedicated networking hours and engage directly with C-suites, VPs of R&D, and translational heads driving first-in-human trials.
Industry News
Altos Labs Secures Record $3 Billion to Drive Cellular Reprogramming
Altos Labs raised an unprecedented $3 billion in Series A funding to advance partial epigenetic reprogramming therapies. The company aims to restore cell health and resilience, targeting neurodegenerative and immune-related aging disorders.
Insilico Medicine Raises $110 Million to Accelerate AI-Driven Longevity Drug Discovery
Insilico Medicine secured $110 million to expand its AI-powered drug discovery platform focused on aging-related diseases. The funding underscores growing investor confidence in computational biology as a driver of next-generation therapeutics.
M42 Invests in Juvenescence to Accelerate AI-Enabled Longevity Drug Development
M42 announced a strategic investment and partnership with Juvenescence to co-develop AI-enabled therapeutics targeting aging biology. The collaboration aims to fast-track clinical trials and expand global longevity research capabilities.
HAYA Therapeutics Raises $65M to Develop RNA-Guided Medicines for Age-Related Diseases
HAYA Therapeutics secured $65 million in Series A funding, led by Sofinnova Partners and Earlybird Venture Capital, with Eli Lilly participating. Funds will advance HTX-001, a first-in-class therapy targeting heart failure and expand its RNA-guided platform for chronic and age-related conditions.